Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Misses on EPS, Stock Down 3.54%

Crinetics Pharmaceuticals reported a loss of $0.37 per share, but did not provide revenue figures or guidance. The stock reacted negatively, declining by 3.54%, indicating investor uncertainty following the earnings report. The lack of additional commentary from management may have contributed to the stock's downward movement.